Estudo morfofuncional e dos mediadores inflamatórios envolvidos na patogênese da mucosite intestinal induzida por irinotecano (CPT-11) em camundongos : papel da caspase-1, interleucina-18 e óxido nitríco

• Ano de defesa: 2008
• Autor(a) principal: Lima Júnior, Roberto César Pereira
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Palavras-chave em Português: Mucosite; Fator de Ativação de Plaquetas; Mediadores da Inflamação; Inflamação; Citocinas
• Link de acesso: http://www.repositorio.ufc.br/handle/riufc/3843

Severe Intestinal Mucositis (IM) and diarrhea are frequent and dose-limiting side-effects of colon cancer chemotherapy with irinotecan (CPT-11). At present, much of IM pathophysiology remains unknown. Aims: To study the mechanisms and inflammatory mediators involved in CPT-11-induced intestinal mucositis, verifying the role of the protease caspase-1, cytokines interleukin-1 (IL-1), interleukin-18 (IL-18) and interleukin-33 (IL-33), nitric oxide, 5-lipoxygenase and PAF as well as the sequence of activation of these mediators in the inflammatory response and morphofunctional contexts. Methods: Swiss, C57BL/6 (BL), BALB/c (BC) male mice or caspases-1(Casp-1-/-), IL-18 (IL-18-/-), inducible nitric oxide synthase (iNOS-/-), 5-Lipoxygenase (5-LOX-/-), PAF receptor (PAFr-/-) knockout mice, 22g, were divided into groups (n=4-5) and treated for 4 days with saline (5 mL/kg, i.p.) or CPT-11 (60 mg/kg, i.p.) or were given IL-18bp (IL-18 binding protein, 200 µg/animal/4 days, i.p.), aminoguanidine (AG, 50 mg/kg, s.c, 2x/day/4 days), IL-33 (1 µg/animal/4 days, i.v, 1h previously CPT-11) or loperamide ([4x3 mg/kg and 4x30 mg/kg]/animal, s.c.) co-administered with CPT-11. On day 5, diarrhea and leukocyte counts were assessed, and following sacrifice duodenal portions of the animal were collected to assess myeloperoxidase (MPO, neutrophils/mg tissue) and nitric oxide synthase (iNOS pM citruline /h/mg protein) activity, morphometric analysis, and in vitro contractility (%contraction in relation to KCl 60 mM). ANOVA/Newman Keuls or Kruskal Wallis/Dunn were used as statistical tests. P<0.05 was accepted. Results: IM was morphofunctionally similar in both BL and Swiss. CPT-11 induced leukopenia in all animal lineages despite the treatment given. Additionally, CPT-11 induced MPO, increased in vitro contractility and diarrheic events, and villi/crypt ratio reduction in BL and BC mice in comparison with saline treated mice (p<0.05). Despite the injection of CPT-11, Casp-1-/-, IL-18-/- or IL-18bp treated BC mice presented reduced MPO and iNOS activities and also increased villi/crypt ratio, reduced duodenal in vitro contractility and mild diarrhea similar to saline-treated mice (P>0.05), similar to the patterns seen in IL-33 treated mice. The reduced iNOS activity found in the earlier mice led us to investigate the CPT-11 effect on iNOS /- and aminoguanidine-treated mice. Lower IL-1beta and KC cytokine levels, as well as reduced MPO activity were found. Also, preserved villi/crypt ratio and muscle layer thickness, normal duodenal contractility and diarrheic events were seen similarly to saline-treated mice (p>0.05). However, CPT-11-treated PAFr-/- presented morphofunctional alterations and increased intestinal MPO activity. 5-LOX-/- or loperamide treated mice (positive control), both injected with CPT-11, exhibited increased MPO activity and morphometric alterations, but no exacerbation on in vitro contractility was observable. Conclusion: Taken together, these results suggest the role of caspase-1/Interleukin-18/nitric oxide cascade on pathogenesis of CPT-11-induced morphofunctional alteration and inflammatory response (IM). IL-33 seems to be a compensatory protective factor on this inflammatory cascade. 5-LOX and PAFr show a likely secondary role on IM pathophysiology.